Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) Stock Short Interest Declines 66.3%

Hong Kong Pharma Digital Technology Holdings Limited (NASDAQ:HKPD) was the recipient of a large decline in short interest during the month of September. As of September 30th, there was short interest totaling 67,129 shares, a decline of 66.3% from the September 15th total of 199,073 shares. Based on an average daily trading volume, of 2,041,132 shares, the short-interest ratio is presently 0.0 days. Approximately 0.4% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut shares of Hong Kong Pharma Digital Technology from a “sell (d)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. One research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has a consensus rating of “Sell”.

Hong Kong Pharma Digital Technology Price Performance

NASDAQ:HKPD traded down $0.01 during trading hours on Monday, hitting $0.10. 207,628 shares of the company were exchanged, compared to its average volume of 1,374,354. Hong Kong Pharma Digital Technology has a 52-week low of $0.10 and a 52-week high of $1.72. The company has a quick ratio of 3.75, a current ratio of 3.86 and a debt-to-equity ratio of 0.01. The company’s 50 day moving average price is $0.24 and its 200-day moving average price is $0.42.

Hong Kong Pharma Digital Technology (NASDAQ:HKPD) last posted its quarterly earnings results on Friday, August 7th. The company reported ($0.04) earnings per share (EPS) for the quarter. The business had revenue of $3.15 million for the quarter.

About Hong Kong Pharma Digital Technology

Hong Kong Pharma is an exempted limited liability company formed under the laws of the Cayman Islands on August 17, 2023. As a holding company with no material operations of its own, Hong Kong Pharma conducts its operations through its wholly owned subsidiaries, Joint Cross Border Logistics Company Limited and V-Alliance Technology Supplies Limited, each a limited liability corporation incorporated in Hong Kong and collectively referred to as HK Subsidiaries. Our business offering consists of two main categories: (i) OTC pharmaceutical cross-border e-commerce supply chain services, primarily conducted through our Hong Kong subsidiary, Joint Cross Border, which we refer to as the “Supply Chain Services” division and (ii) OTC pharmaceutical cross-border procurement and distribution, primarily conducted through our Hong Kong subsidiary, V-Alliance, which we refer to as the “Procurement and Distribution” division.